Low dose hypericin-PDT induces complete tumor regression in BALB/c mice bearing CT26 colon carcinoma

Photodiagnosis and Photodynamic Therapy

Volumn 8, Issue 4, 2011, Pages 291-296

  Sanovic, Renata ^a   Verwanger, Thomas ^b   Hartl, Arnulf ^a   Krammer, Barbara ^b  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF SALZBURG   (Austria)

Author keywords

Antitumoral immune response; BALB c mice bearing CT26; Hypericin; Low dose photodynamic therapy; Vascular damage

Indexed keywords

HYPERICIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; COLON CARCINOMA; CONTROLLED STUDY; DISEASE CONTROL; DISEASE COURSE; DRUG EFFECT; FEMALE; IMMUNE RESPONSE; IN VIVO STUDY; INOCULATION; LOW DRUG DOSE; MOUSE; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR REGRESSION;

ANIMALS; CELL LINE, TUMOR; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; MICE; MICE, INBRED BALB C; PERYLENE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; REMISSION INDUCTION; TREATMENT OUTCOME;

ANIMALIA; MURINAE; MUS;

EID: 84855927363     PISSN: 15721000     EISSN: 18731597     Source Type: Journal    
DOI: 10.1016/j.pdpdt.2011.04.003     Document Type: Article

References (28)

1. Gomer C.J. Preclinical examination of first and second generation photosensitizers used in photodynamic therapy. Photochem Photobiol 1991, 54:1093-1107.
2. Keller S.M. Photodynamic therapy. Biology and clinical application. Chest Surg Clin N Am 1995, 5:121-137.
3. Dougherty T.J. An update on photodynamic therapy applications. J Clin Laser Med Surg 2002, 20:3-7.
4. Patrice T., Olivier D., Bourre L. PDT in clinics: indications, results, and markets. J Environ Pathol Toxicol Oncol 2006, 25:467-485.
5. Buytaert E., Dewaele M., Agostinis P. Molecular effectors of multiple cell death pathways initiated by photodynamic therapy. Bba-Rev Cancer 2007, 1776:86-107.
6. Henderson B.W., Dougherty T.J. How does photodynamic therapy work?. Photochem Photobiol 1992, 55:145-157.
7. Butterweck V., Schmidt M. St. John's wort: role of active compounds for its mechanism of action and efficacy. Wien Med Wochenschr 2007, 157:356-361.
8. Obach R.S. Inhibition of human cytochrome P450 enzymes by constituents of St. John's wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther 2000, 294:88-95.
9. Galeotti N., Vivoli E., Bilia A.R., Vincieri F.F., Ghelardini C. St. John's Wort reduces neuropathic pain through a hypericin-mediated inhibition of the protein kinase C gamma and epsilon activity. Biochem Pharmacol 2010, 79:1327-1336.
10. Karioti A., Bilia A.R. Hypericins as potential leads for new therapeutics. Int J Mol Sci 2010, 11:562-594.
11. Engelhardt V., Krammer B., Plaetzer K. Antibacterial photodynamic therapy using water-soluble formulations of hypericin or mTHPC is effective in inactivation of Staphylococcus aureus. Photochem Photobiol Sci 2010, 9:365-369.
12. Saw C.L., Heng P.W., Olivo M. Potentiation of the photodynamic action of hypericin. J Environ Pathol Toxicol Oncol 2008, 27:23-33.
13. Blank M., Lavie G., Mandel M., Keisari Y. Effects of photodynamic therapy with hypericin in mice bearing highly invasive solid tumors. Oncol Res 2000, 12:409-418.
14. Chen B., Xu Y., Roskams T., et al. Efficacy of antitumoral photodynamic therapy with hypericin: relationship between biodistribution and photodynamic effects in the RIF-1 mouse tumor model. Int J Cancer 2001, 93:275-282.
15. Gollnick S.O., Brackett C.M. Enhancement of anti-tumor immunity by photodynamic therapy. Immunol Res 2010, 46:216-226.
16. Castano A.P., Mroz P., Hamblin M.R. Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer 2006, 6:535-545.
17. Gollnick S.O., Vaughan L., Henderson B.W. Generation of effective antitumor vaccines using photodynamic therapy. Cancer Res 2002, 62:1604-1608.
18. Korbelik M., Sun J.H. Photodynamic therapy-generated vaccine for cancer therapy. Cancer Immunol Immunother 2006, 55:900-909.
19. Chen B., Pogue B.W., Hoopes P.J., Hasan T. Vascular and cellular targeting for photodynamic therapy. Crit Rev Eukaryot Gene Expr 2006, 16:279-305.
20. Chen B., Roskams T., de Witte P.A. Antivascular tumor eradication by hypericin-mediated photodynamic therapy. Photochem Photobiol 2002, 76:509-513.
21. Olivo M., Chin W. Perylenequinones in photodynamic therapy: cellular versus vascular response. J Environ Pathol Toxicol Oncol 2006, 25:223-237.
22. Blank M., Kostenich G., Lavie G., Kimel S., Keisari Y., Orenstein A. Wavelength-dependent properties of photodynamic therapy using hypericin in vitro and in an animal model. Photochem Photobiol 2002, 76:335-340.
23. Krammer B. Vascular effects of photodynamic therapy. Anticancer Res 2001, 21:4271-4277.
24. Chen B., Roskams T., Xu Y., Agostinis P., de Witte P.A. Photodynamic therapy with hypericin induces vascular damage and apoptosis in the RIF-1 mouse tumor model. Int J Cancer 2002, 98:284-290.
25. Sosa S., Pace R., Bornancin A., et al. Topical anti-inflammatory activity of extracts and compounds from Hypericum perforatum L. J Pharm Pharmacol 2007, 59:703-709.
26. Korbelik M. Induction of tumor immunity by photodynamic therapy. J Clin Laser Med Surg 1996, 14:329-334.
27. Chen W.R., Huang Z., Korbelik M., Nordquist R.E., Liu H. Photoimmunotherapy for cancer treatment. J Environ Pathol Toxicol Oncol 2006, 25:281-291.
28. Preise D., Scherz A., Salomon Y. Antitumor immunity promoted by vascular occluding therapy: lessons from vascular-targeted photodynamic therapy (VTP). Photochem Photobiol Sci 2011.